Detalles de la búsqueda
1.
SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
Ophthalmology
; 130(10): 1066-1072, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37220815
2.
One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry.
Ophthalmology
; 130(9): 937-946, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37086857
3.
Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab.
Ophthalmology
; 130(8): 795-803, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36990322
4.
SCORE2 Report 17: Macular thickness fluctuations in anti-VEGF-treated patients with central or hemiretinal vein occlusion.
Graefes Arch Clin Exp Ophthalmol
; 260(5): 1491-1500, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34842984
5.
Disease-modifying effects of ranibizumab for central retinal vein occlusion.
Graefes Arch Clin Exp Ophthalmol
; 260(3): 799-805, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34613454
6.
Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial.
Graefes Arch Clin Exp Ophthalmol
; 259(7): 1839-1851, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33415354
7.
8.
LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALS.
Retina
; 39(9): 1802-1809, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29746405
9.
The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.
Ophthalmology
; 124(5): 596-603, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28284785
10.
SCORE2 Report 2: Study Design and Baseline Characteristics.
Ophthalmology
; 124(2): 245-256, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27863843
11.
Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
JAMA
; 317(20): 2072-2087, 2017 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28492910
12.
Diagnostic and Therapeutic Challenges.
Retina
; 41(3): 665-667, 2021 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31895072
13.
Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
Ophthalmology
; 122(4): 779-86, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25601535
14.
Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ophthalmology
; 122(2): 367-74, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25439595
15.
Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
Retina
; 34(12): 2439-43, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24999721
16.
Month 60 Imaging Findings and Relationship to Treatment Outcomes Following Anti-VEGF Therapy for Macular Edema Due to Central or Hemi-Retinal Vein Occlusion.
Am J Ophthalmol
; 260: 147-159, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38061584
17.
Association of Retinal Thickness at Month 1 Post-Treatment with Later Thickness and Visual Acuity in Central Vein Occlusion.
Am J Ophthalmol
; 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38705553
18.
Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry.
Ophthalmol Ther
; 13(5): 1357-1368, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38520643
19.
Considerations for the Identification and Management of Geographic Atrophy: Recommendations from an Expert Panel.
Clin Ophthalmol
; 18: 325-335, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38332904
20.
The Wisconsin silicone oil study (report #1): anatomical and functional outcomes of repair of retinal detachment with proliferative vitreoretinopathy.
Eye (Lond)
; 2024 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38745084